EBRD and partners acquire Egypt’s Adwia Pharmaceuticals

By Nibal Zgheib

Share this page:

  • EBRD, DPI and CDC Group create a new investment platform to invest in pharmaceuticals
  • EBRD commits to initial capital of US$ 250 million
  • The platform acquires Egyptian generic-drug maker Adwia Pharmaceuticals and Celon in India

The European Bank for Reconstruction and Development (EBRD) is joining forces with reputable partners to improve the availability and affordability of medicines, using an investment platform with an initial capital commitment of US$ 250 million.

The EBRD is supporting the platform’s growth in Egypt, alongside Development Partners International (DPI), a pan-African private equity firm, and CDC Group, a development finance institution funded by the UK government.

As a first step for the investment platform the partners have acquired Adwia Pharmaceuticals, an Egyptian manufacturer of generic drugs, and Celon Laboratories, an Indian oncology and critical-care product specialist. Adwia will benefit from Celon’s know-how in drug development, including for chronic and life-threatening health conditions.

This investment will also help Adwia Pharmaceuticals to expand and modernise its manufacturing assets, introduce products with higher added value and improve its health and safety standards, product quality and governance in Egypt.

The founding shareholders plan to increase their impact by further expanding the investment platform’s activities.

Egypt is a founding member of the EBRD. Since the start of the Bank’s operations there in 2012, the EBRD has invested over €7 billion in 125 projects in the country.

Share this page: